Compare BTOC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | INBX |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 430.2M |
| IPO Year | 2024 | 2020 |
| Metric | BTOC | INBX |
|---|---|---|
| Price | $0.61 | $85.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.6K | ★ 237.4K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $197,399,541.00 | $1,400,000.00 |
| Revenue This Year | $34.89 | $563.00 |
| Revenue Next Year | $14.53 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.35 | N/A |
| 52 Week Low | $0.41 | $10.81 |
| 52 Week High | $5.69 | $94.47 |
| Indicator | BTOC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 59.17 |
| Support Level | $0.60 | $74.80 |
| Resistance Level | $0.72 | $94.47 |
| Average True Range (ATR) | 0.05 | 6.36 |
| MACD | 0.01 | -1.27 |
| Stochastic Oscillator | 42.53 | 62.68 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.